velcade

Drug maker Celgene (CELG) says its multiple myeloma cancer pill reduced the risk of progression by half among newly diagnosed patients who used the drug and chemotherapy compared with those who only used chemotherapy.

There must be holiday cheer in the executive suite at biotech Celgene (CELG), where the stock is up 15% over last year. The Summit, N.J.-based company's cancer pill Revlimid generated $1.3 billion in sales last year. And it did so as a backup therapy for patients with the blood cancer multiple...